U.S. Capital Wealth Advisors LLC Cuts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• U.S. Capital Wealth Advisors LLC reduced its stake in Alnylam Pharmaceuticals, Inc. by 7.1%, selling 3,984 shares and ending the quarter with 52,027 shares valued at approximately $16.97 million.
• Insider trading reports indicate significant sales, including EVP Jeffrey V. Poulton selling 2,274 shares for over $1 million, marking a 4.34% decrease in his ownership.
• Alnylam Pharmaceuticals recently had a strong quarterly earnings report, with earnings per share of $0.32 that surpassed estimates significantly, prompting several analysts to raise their price targets.

U.S. Capital Wealth Advisors LLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,027 shares of the biopharmaceutical company's stock after selling 3,984 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $16,965,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in ALNY. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at $69,292,000. Adage Capital Partners GP L.L.C. lifted its position in Alnylam Pharmaceuticals by 203.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company's stock valued at $76,195,000 after purchasing an additional 189,128 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after buying an additional 185,783 shares during the period. Finally, SCS Capital Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $46,194,000. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,979 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the transaction, the chief executive officer directly owned 56,221 shares in the company, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Pushkal Garg sold 1,455 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the transaction, the executive vice president directly owned 20,221 shares in the company, valued at $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,594 shares of company stock worth $33,968,256. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded up $5.36 during trading hours on Monday, hitting $458.92. The stock had a trading volume of 971,754 shares, compared to its average volume of 1,104,943. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $484.21. The firm has a 50-day moving average price of $417.91 and a 200 day moving average price of $326.74. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market capitalization of $60.16 billion, a price-to-earnings ratio of -185.80 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the firm earned ($0.13) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent research reports. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research report on Friday, August 1st. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price objective for the company in a research note on Monday, August 4th. Finally, Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $439.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.